Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of AD-212-A vs AD-2121 in Healthy Volunteers
NCT06025773Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BC LisPram in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve over a dosing interval at steady state at 7 days and Percent Decrease from baseline of Integrated gastric acidity at 7 days. Started Sep 2023; status: completed.
02
Drugs
BC LisPram
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06025773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025773.